External validation of three diabetes prediction scores in a Spanish cohort: does adding high risk for depression improve the validation of the FINDRISC score (FINDRISC-MOOD)?

Objectives To evaluate the external validity of the FINDRISC, DESIR and ADA risk scores for the prediction of diabetes in a Spanish population aged >45 years and to test the possible improvement of FINDRISC by adding a new variable of high risk of depression when Patient Health Questionnaire-9 (P...

Descripción completa

Detalles Bibliográficos
Autores: Salinero Fort, Miguel A., Mostaza Prieto, José María, Lahoz Rallo, Carlos, Cárdenas Valladolid, Juan, Iriarte Campo, Víctor, Estirado de Cabo, Eva, García Iglesias, Francisca, González Alegre, Teresa, Cornejo del Río, Víctor M., Sanchez Arroyo, Vanesa, Sabín Rodríguez, Concesa, López López, Silvia, Gómez Campelo, Paloma, Taulero Escalera, Belén, Rodríguez Artalejo, Fernando, San Andrés Rebollo, F. Javier, de Burgos Lunar, Carmen, SPREDIA- 2 Group
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/754120
Acceso en línea:https://hdl.handle.net/10486/754120
https://dx.doi.org/10.1136/bmjopen-2023-083121
Access Level:acceso abierto
Palabra clave:Diabetes Mellitus, Type 2
Blood Glucose / metabolism
Glucose Tolerance Test
Patient Health Questionnaire
ROC Curve
Medicina
Descripción
Sumario:Objectives To evaluate the external validity of the FINDRISC, DESIR and ADA risk scores for the prediction of diabetes in a Spanish population aged >45 years and to test the possible improvement of FINDRISC by adding a new variable of high risk of depression when Patient Health Questionnaire-9 (PHQ-9) questionnaire score ≥10 (FINDRISC-MOOD). Design Prospective population-based cohort study. Setting 10 primary healthcare centres in the north of the city of Madrid (Spain). Participants A total of 1242 participants without a history of diabetes and with 2-hour oral glucose tolerance test (OGTT) plasma glucose <200 mg/dL (<11.1 mmol/L) were followed up for 7.3 years (median) using their electronic health records (EHRs) and telephone contact. Primary and secondary outcome measures Diabetes risk scores (FINDRISC, DESIR, ADA), PHQ-9 questionnaire and 2-hour-OGTT were measured at baseline. Incident diabetes was defined as treatment for diabetes, fasting plasma glucose ≥126 mg/dL (≥7.0 mmol/L), new EHR diagnosis or self-reported diagnosis. External validation was performed according to optimal cut-off, sensitivity, specificity and Youden Index. Comparison between diabetes risk scores, including FINDRISC-MOOD (original FINDRISC score plus five points if PHQ-9 ≥10), was measured by area under the receiver operating characteristic curve (AUROC). Results During follow-up, 104 (8.4%; 95% CI, 6.8 to 9.9) participants developed diabetes and 185 had a PHQ-9 score ≥10. The AUROC values were 0.70 (95% CI, 0.67 to 0.72) for FINDRISC-MOOD and 0.68 (95% CI, 0.65 to 0.71) for the original FINDRISC. The AUROCs for DESIR and ADA were 0.66 (95% CI, 0.63 to 0.68) and 0.66 (95% CI, 0.63 to 0.69), respectively. There were no significant differences in AUROC between FINDRISC-MOOD and the other scores. Conclusions The results of FINDRISC-MOOD were like those of the other risk scores and do not allow it to be recommended for clinical use